Despite the oncogenic role that Bcr-Abl plays in hematopoietic malignancies like CML, activated c-Abl has been reported to be involved in the progression of solid tumors such as non-small cell lung cancer (NSCLC) [39] and breast cancer [30, 31]. This evidence concerns the gene ABL1 and non-small cell lung carcinoma.